---
title: "Changshan Biochemical Pharmaceutical Enrolls First Patient in Drug Trial"
date: "2025-02-14 10:51:47"
summary: "Hebei Changshan Biochemical Pharmaceutical enrolled the first participant in the phase one clinical trial for CSCJC3456 tablets. The trial will evaluate the use of the drug in patients with advanced malignant solid tumors, according to a Friday filing with the Shenzhen bourse. Shares of the pharmaceutical company rose more than..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Hebei Changshan Biochemical Pharmaceutical enrolled the first participant in the phase one clinical trial for CSCJC3456 tablets.

The trial will evaluate the use of the drug in patients with advanced malignant solid tumors, according to a Friday filing with the Shenzhen bourse.

Shares of the pharmaceutical company rose more than 3% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250213:G2467710:0/)
